Edition:
United Kingdom

Catalyst Pharmaceuticals Inc (CPRX.OQ)

CPRX.OQ on NASDAQ Stock Exchange Capital Market

5.76USD
16 Aug 2019
Change (% chg)

$0.40 (+7.46%)
Prev Close
$5.36
Open
$5.35
Day's High
$5.78
Day's Low
$5.35
Volume
395,878
Avg. Vol
458,729
52-wk High
$6.16
52-wk Low
$1.85

Latest Key Developments (Source: Significant Developments)

Catalyst Pharmaceuticals Q2 Earnings Per Share $0.10
Wednesday, 7 Aug 2019 

Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 EARNINGS PER SHARE $0.10.Q2 EARNINGS PER SHARE ESTIMATE $0.03 -- REFINITIV IBES DATA.ENDED JUNE 30, 2019 WITH $64.9 MILLION IN CASH AND INVESTMENTS AND NO FUNDED DEBT.CATALYST PHARMACEUTICALS - BELIEVES EXISTING CAPITAL RESOURCES WILL BE SUFFICIENT TO SUPPORT ITS PLANNED OPERATIONS FOR AT LEAST NEXT 12 MONTHS.PRODUCT REVENUE, NET IN Q2 2019 WAS $28.8 MILLION.  Full Article

Catalyst Pharmaceuticals Files Federal Lawsuit Against U.S. Food And Drug Administration
Wednesday, 12 Jun 2019 

June 12 (Reuters) - Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS FILES FEDERAL LAWSUIT AGAINST U.S. FOOD AND DRUG ADMINISTRATION.CATALYST - LAWSUIT CHALLENGING RECENT APPROVAL OF NDA AND RELATED DRUG LABELING FOR JACOBUS PHARMACEUTICAL COMPANY'S DRUG RUZURGI.CATALYST PHARMACEUTICALS INC - COMPLAINT WAS FILED IN U.S. DISTRICT COURT FOR SOUTHERN DISTRICT OF FLORIDA.CATALYST PHARMACEUTICALS INC - AMONG OTHER REMEDIES, SUIT SEEKS AN ORDER VACATING FDA'S APPROVAL OF RUZURGI.  Full Article

Catalyst Pharmaceuticals Announces Expansion Of Firdapse License To Include Japan
Thursday, 30 May 2019 

May 30 (Reuters) - Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS ANNOUNCES EXPANSION OF FIRDAPSE LICENSE TO INCLUDE JAPAN.CATALYST PHARMACEUTICALS INC - WILL PAY ROYALTIES OF A SIMILAR PERCENTAGE OF ITS NET REVENUES DERIVED IN JAPAN AS IN ITS ORIGINAL LICENSE AGREEMENT..CATALYST PHARMACEUTICALS- UPON ACHIEVEMENT OF CERTAIN MILESTONE IN JAPAN, CO TO HAVE OPTION TO EXPAND TO INCLUDE MOST OF ASIA, CENTRAL & SOUTH AMERICA.  Full Article

Catalyst Pharmaceuticals Reports Q1 Results
Monday, 13 May 2019 

May 13 (Reuters) - Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.01.Q1 EARNINGS PER SHARE ESTIMATE $-0.13 -- REFINITIV IBES DATA.AT MARCH 31, 2019, CATALYST HAD CASH AND CASH EQUIVALENTS AND INVESTMENTS OF $50.6 MILLION AND NO FUNDED-DEBT.CONTINUE TO MAKE PROGRESS IN CLINICAL DEVELOPMENT OF PIPELINE OF OTHER POTENTIAL INDICATIONS FOR FIRDAPSE.TOTAL NET REVENUE IN Q1 2019 WAS $12.4 MILLION..TOTAL NET REVENUE IN Q1 2019 WAS $12.4 MILLION.  Full Article

Catalyst Pharmaceuticals Says Qtrly Loss Per Share $0.14
Monday, 18 Mar 2019 

March 18 (Reuters) - Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND YEAR-END 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 GAAP LOSS PER SHARE $0.14.Q4 EARNINGS PER SHARE ESTIMATE $-0.12 -- REFINITIV IBES DATA.AT DECEMBER 31, 2018, CATALYST HAD CASH AND INVESTMENTS OF $58.5 MILLION AND NO DEBT.  Full Article

Catalyst Pharmaceuticals Announces Definitive Agreement With Endo For Vigabatrin Tablets
Tuesday, 18 Dec 2018 

Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS ANNOUNCES DEFINITIVE AGREEMENT WITH ENDO FOR VIGABATRIN TABLETS.CATALYST PHARMACEUTICALS INC - WILL RECEIVE AN UP-FRONT PAYMENT, MILESTONE PAYMENTS BASED ON ACHIEVEMENT OF REGULATORY APPROVALS.CATALYST PHARMACEUTICALS INC - UNDER DEAL, CO TO ALSO RECEIVE SHARING OF DEFINED NET PROFITS UPON COMMERCIALIZATION.CATALYST PHARMACEUTICALS - SIGNED AGREEMENT WITH ENDO INTERNATIONAL'S UNIT FOR FURTHER DEVELOPMENT,COMMERCIALIZATION OF GENERIC SABRIL TABLETS.  Full Article

FDA Grants Approval Of Firdapse To Catalyst Pharmaceuticals
Wednesday, 28 Nov 2018 

Nov 28 (Reuters) - U.S. Food and Drug Administration::FDA APPROVES FIRST TREATMENT FOR LAMBERT-EATON MYASTHENIC SYNDROME, A RARE AUTOIMMUNE DISORDER.FDA SAYS GRANTED APPROVAL OF FIRDAPSE TO CATALYST PHARMACEUTICALS INC.  Full Article

Catalyst Pharmaceuticals Announces Firdapse (Amifampridine) New Drug Application Continues Under Review
Tuesday, 27 Nov 2018 

Nov 27 (Reuters) - Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS ANNOUNCES FIRDAPSE® (AMIFAMPRIDINE) NEW DRUG APPLICATION CONTINUES UNDER REVIEW.CATALYST PHARMACEUTICALS INC - NO DECISION HAS YET BEEN RECEIVED FROM FDA WITH RESPECT TO COMPANY'S NEW DRUG APPLICATION FOR FIRDAPSE.CATALYST PHARMA - CONTRACTOR WORKING ON A WEB PAGE UNINTENTIONALLY ALLOWED LIVE SCREEN TO BE SEEN SHOWING POSSIBLE APPROVAL OF CO'S NDA ALREADY RECEIVED.  Full Article

Catalyst Pharmaceuticals Q2 GAAP Loss Per Share $0.06
Tuesday, 7 Aug 2018 

Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 GAAP LOSS PER SHARE $0.06.Q2 EARNINGS PER SHARE VIEW $-0.08 -- THOMSON REUTERS I/B/E/S.POTENTIAL LAUNCH OF FIRDAPSE FOR LEMS IN EARLY 2019.EXPECTS THAT COSTS RELATED TO RESEARCH AND DEVELOPMENT ACTIVITIES WILL CONTINUE TO BE SUBSTANTIAL THROUGHOUT 2018.CATALYST PHARMACEUTICALS - BELIEVES EXISTING CAPITAL RESOURCES WILL BE SUFFICIENT TO SUPPORT PLANNED OPERATIONS THROUGH 2019.  Full Article

Catalyst Pharma Submits NDA For Firdapse
Thursday, 29 Mar 2018 

March 29 (Reuters) - Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR FIRDAPSE® FOR TREATMENT OF LAMBERT-EATON MYASTHENIC SYNDROME.CATALYST PHARMACEUTICALS - SUBMISSION OF NDA TO U.S. FDA FOR FIRDAPSE.  Full Article

UPDATE 2-Catalyst Pharma sues FDA over approval of cheaper rival drug

June 12 Catalyst Pharmaceuticals Inc, which has come under fire for the high price tag on its rare disease drug, on Wednesday sued the U.S. Food and Drug Administration to challenge the recent approval of a lower-cost rival drug.